Neuroblastoma Maintenance Therapy Trial (NCT02679144)
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
🩺 Plain-English Summary (8th-Grade Level)
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Who can join: Review the eligibility criteria below.
Location: University of Alabama, Children's of Alabama — Birmingham, Alabama
Age range: 1 Year to 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (48 Sites)
Showing the first 25 of 48 sites.
- University of Alabama, Children's of Alabama — Birmingham, Alabama
- Arkansas Children's Hospital — Little Rock, Arkansas
- UCSF Benioff Children's Hospital Oakland- — Oakland, California
- Rady Children's Hospital — San Diego, California
- Rocky Mountain Pediatric Hematology — Denver, Colorado
- Connecticut Children's Hospital — Hartford, Connecticut
- University of Florida — Gainesville, Florida
- Arnold Palmer Hospital for Children — Orlando, Florida
- All Children's Hospital Johns Hopkins Medicine — St. Petersburg, Florida
- St. Joseph's Children's Hospital — Tampa, Florida
- Augusta University Health — Augusta, Georgia
- Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
- St. Lukes — Boise, Idaho
- Advocate Aurora Research Institute — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- Kentucky Children's Hospital — Lexington, Kentucky
- Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine — Louisville, Kentucky
- Tufts Medical Center — Boston, Massachusetts
- Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Children's Hospital and Clinics of Minnesota — Minneapolis, Minnesota
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- NYU Langone Health Hassenfeld Children's Hospital — New York, New York
- The Children's Hospital at Montefiore — The Bronx, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroblastoma
- Open-Label Study of 18F-mFBG for Imaging Neuroblastoma — Los Angeles, California
- Neuroblastoma Precision Trial — Los Angeles, California
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow — Indianapolis, Indiana
- A Study of N9 Chemotherapy in Children With Neuroblastoma — New York, New York
- A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma — San Francisco, California
Explore by condition: All Neuroblastoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.